News & Videos

"After more than 50 years leading the fight to legitimize attention deficit hyperactivity disorder, Keith Conners could be celebrating.

 

Severely hyperactive and impulsive children, once shunned as bad seeds, are now recognized as having a real neurological problem. Doctors and parents have largely accepted drugs like Adderall and Concerta to temper the traits of classic A.D.H.D., helping youngsters succeed in school and beyond.

 

But Dr. Conners did not feel triumphant this fall as he addressed a group of fellow A.D.H.D. specialists in Washington. He noted that recent data from the Centers for Disease Control and Prevention show that the diagnosis had been made in 15 percent of high school-age children, and that the number of children on medication for the disorder had soared to 3.5 million from 600,000 in 1990. He questioned the rising rates of diagnosis and called them “a national disaster of dangerous proportions.”

 

“The numbers make it look like an epidemic. Well, it’s not. It’s preposterous,” Dr. Conners, a psychologist and professor emeritus at Duke University, said in a subsequent interview. “This is a concoction to justify the giving out of medication at unprecedented and unjustifiable levels.”

 

http://www.nytimes.com/2013/12/15/health/the-selling-of-attention-deficit-disorder.html?_r=0

"The current open question in the New Parent, Old Parent collaboration between Motherlode and Booming brought forth some of the most helpful advice I’ve ever seen from a “crowdsource.” I asked,“How do you know when it’s time to get professional help for a child who is anxious, depressed or angry beyond her years?”

 

Behind the scenes, I was a little worried about that as a question. On the one hand, it seemed vague. How old a child? What kind of problems? But I had a sense that for many parents who had chosen to find outside help for a child who was struggling emotionally, there must have been a moment — a point when the ordinary seemed to tip over into the extraordinary, and it became clear that reaching out would help. I thought others, looking back, might have something to say about the moment when they could have sought outside help, or the ways that help failed, or why they considered and rejected the idea."

Read more here...

"Fred Maxik wants to make a light bulb that will help you sleep.

“Biological specific lights,” tuned so as not to interfere with an individual’s normal production of melatonin, the hormone secreted from the pineal gland linked to sleepiness, could begin to hit the market in about two years, according to Mr. Maxik, a founder of theLighting Science Group, which specializes in LED bulbs.

With a biological bulb, you could read at night without experiencing the nagging irritability that can occur after using a computer or sitting close to a lamp near bedtime.

And other bulbs — or the same bulb programmed via a network— could help make consumers feel more refreshed in the morning by choreographing their wake-up ritual. “We could even do things like lights for sterilization, with photo catalysts” for bathrooms in perhaps five to six years, he added.

While solid state lights and LED bulbs have been promoted as a tools for energy conservation, industry experts and executives suggest that efficiency will become a Trojan horse for a host of unexpected and arguably more valuable applications. Light-emitting diodes, after all, are semiconductors that can be programmed to emit light at precise wavelengths, colors and tones. Traditional light bulbs, the last vestige of the vacuum tube era, produce light with hot gases or wires."

http://green.blogs.nytimes.com/2011/10/07/a-new-use-for-leds-mind-control/?_r=1

Brain ‘training’ gains currency as treatment for disease and to ease effects of aging.


"If you’d asked me eight to nine years ago if I believe in cognitive training, I’d have said ‘pfft.’ But the research is quite convincing,” said Bonnie Wong, a clinical neuropsychologist at Beth Israel Deaconess Medical Center"

http://sharpbrains.com/blog/2013/07/15/brain-training-going-mainstream-new-center-at-beth-israel-deaconess-medical-center/

 

Research published recently from the University of Texas has demonstrated the mechanism of action of Low-level light/laser therapy (LLLT) using red-to-near-infrared wavelengths of light to modulate neurobiological functioning.  This research reinforces the conclusions reached by our own research for 1072nm infrared light therapy that IR light evokes a response from a terminal enzyme that modulates the activity of mitochondria that makes it "an ideal target for cognitive enhancement, as its expression reflects the changes in metabolic capacity underlying higher-order brain functions."


If you would like to participate in our ongoing study on Alzheimer's/Dementia using infrared light please contact us at Email: marvinberman@quietmindfdn.org


Phone: 610-940-0488 


 

Link - http://www.ncbi.nlm.nih.gov/pubmed/23806754


Abstract

Transcranial brain stimulation with low-level light/laser therapy (LLLT) is the use of directional low-power and high-fluency monochromatic or quasimonochromatic light from lasers or LEDs in the red-to-near-infrared wavelengths to modulate a neurobiological function or induce a neurotherapeutic effect in a nondestructive and non-thermal manner. The mechanism of action of LLLT is based on photon energy absorption by cytochrome oxidase, the terminal enzyme in the mitochondrial respiratory chain. Cytochrome oxidase has a key role in neuronal physiology, as it serves as an interface between oxidative energy metabolism and cell survival signaling pathways. Cytochrome oxidase is an ideal target for cognitive enhancement, as its expression reflects the changes in metabolic capacity underlying higher-order brain functions. This review provides an update on new findings on the neurotherapeutic applications of LLLT. The photochemical mechanisms supporting its cognitive-enhancing and brain-stimulatory effects in animal models and humans are discussed. LLLT is a potential non-invasive treatment for cognitive impairment and other deficits associated with chronic neurological conditions, such as large vessel and lacunar hypoperfusion or neurodegeneration. Brain photobiomodulation with LLLT is paralleled by pharmacological effects of low-dose USP methylene blue, a non-photic electron donor with the ability to stimulate cytochrome oxidase activity, redox and free radical processes. Both interventions provide neuroprotection and cognitive enhancement by facilitating mitochondrial respiration, with hormetic dose-response effects and brain region activational specificity. This evidence supports enhancement of mitochondrial respiratory function as a generalizable therapeutic principle relevant to highly adaptable systems that are exquisitely sensitive to energy availability such as the nervous system.

Paris, France - Two Framingham risk scores are more strongly associated with cognitive decline than a dementia risk score and could be a better fit for use in primary prevention in targeting modifiable risk factors, according to new research [1].

The study, published in the April 2, 2013 issue of Neurology, suggests that both the Framingham general cardiovascular disease (CVD) risk profile and especially the Framingham stroke risk profile are more strongly predictive of 10-year cognitive decline than the Cardiovascular Risk Factors, Aging and Dementia (CAIDE) risk score. The Framingham scores could provide physicians with more information about the link between midlife cardiovascular disease risk factors and later cognitive decline to pass on to their patients, said lead author Dr Sara Kaffashian (INSERM Center for Research in Epidemiology and Population Health, Paris, France).

"Physicians can tell patients who have hypertension or high cholesterol levels that they are at high risk of having heart disease or stroke—but they can also tell these patients that their brain may be at risk, too," she said in an interview. "Cardiovascular risk factors should be managed and treated early on, in middle age for example, to have a more favorable effect on cognition."

However, Dr Miia Kivipelto (Karolinska Institutet, Stockholm, Sweden), who helped develop the CAIDE dementia risk score and isn't connected to the current study, said that while she is pleased to see increasing interest in risk scores that predict cognitive decline and dementia, she doesn't believe the scores are conducive to comparison, as they have different outcomes.

These scores were developed to predict different events, are composed of different risk factors and populations, and are calibrated differently, so it's not surprising that their predictive values are different, Kaffashian agreed. She cautioned against concluding that the Framingham scores are necessarily superior to the dementia risk score.

Both Framingham scores include age, systolic blood pressure, hypertension treatment, smoking, and diabetes. The Framingham CVD risk score also includes sex, HDL cholesterol, and total cholesterol. The Framingham stroke risk score incorporates prior CVD, atrial fibrillation, and left ventricular hypertrophy and includes five categories of systolic blood pressure.

The CAIDE risk score was developed to predict late-life dementia based on midlife risk factors, including age, sex, systolic blood pressure, body-mass index, total cholesterol, physical activity, APOE genotype (in one version), and education, a marker of cognitive decline.

Study participants were from Whitehall II, an ongoing prospective cohort study that was established in 1985 and enrolled male and female office-based employees aged 35 to 55 years. The comparison of the Framingham CVD score and CAIDE dementia risk score was based on 4374 participants, while the comparison of the Framingham stroke and CAIDE score included 5157 subjects.

 

-  http://www.theheart.org/article/1525761.do

 

About 11 percent of school-age children in the United States -- and 19 percent of high-school-age boys -- have been diagnosed with attention-deficit/hyperactivity disorder (ADHD), according to U.S. Centers for Disease Control and Prevention data.

The figures show that about 6.4 million children aged 4 to 17 have been diagnosed with ADHD at some point in their lives, a 16 percent rise since 2007 and a 53 percent increase over the past decade, The New York Times reported Sunday.

Also, about two-thirds of kids with a current diagnosis of ADHD take prescription drugs such as Adderall or Ritalin, which can improve the lives of patients, but may also lead to addiction, anxiety and even psychosis, the report said.

The data could add to growing concern among many doctors that the ADHD diagnosis and its drug treatments are overused in American children, according to The Times.

For its story about ADHD rates, the newspaper analyzed raw data from a wider CDC study of children's health issues. It included more than 76,000 parents nationwide who were interviewed from February 2011 to June 2012.

 

"Those are astronomical numbers. I'm floored," Dr. William Graf, a pediatric neurologist in New Haven, Conn., and a professor at the Yale School of Medicine, told The Times.

"Mild symptoms are being diagnosed so readily, which goes well beyond the disorder and beyond the zone of ambiguity to pure enhancement of children who are otherwise healthy," he added.

Another expert agreed. "The marked increase in the number of youth diagnosed with ADHD is undoubtedly due to a multitude of factors. Regrettably, the results from this study do not allow us to identify a single cause, and one has to resist the temptation to lay blame on any one single factor," said Dr. Andrew Adesman, chief of developmental and behavioral pediatrics at the Steven & Alexandra Cohen Children's Medical Center of New York, in New Hyde Park.

He added, "To the extent that problems with inattention, impulsivity, and restlessness can vary wildly in severity, it is likely that the increased number of children and adolescents diagnosed with ADHD reflects a greater number of youth with mild problems being diagnosed and treated."

The data showed that 15 percent of school-age boys and 7 percent of girls had received an ADHD diagnosis. Among teens aged 14 to 17, about 19 percent of boys and 10 percent of girls had been diagnosed with ADHD. About 10 percent of high school boys currently take ADHD medications, The Times reported.

ADHD diagnosis rates in states vary widely. For example, about 23 percent of school-age boys in Southern states -- such as Arkansas, Kentucky, Louisiana, South Carolina and Tennessee -- were diagnosed with ADHD, compared with fewer than 10 percent in Colorado and Nevada.

Historically, ADHD has been estimated to affect 3 percent to 7 percent of children. There is no definitive test for the disorder. Diagnosis is based on extensive interviews with children, parents and teachers, and ruling out other causes, The Times reported.

"These data highlight the importance of obtaining an accurate diagnosis of ADHD in children, adolescents and adults with ADHD. The diagnosis of ADHD needs to be established through careful clinical interview -- there are no shortcuts," said Dr. Lenard Adler, a professor of child and adolescent psychiatry at NYU School of Medicine.

The rising rates of ADHD diagnosis and medication use are due to several factors, according to experts. Some doctors are too quick to diagnose any complaints about inattention as ADHD, drug company advertising emphasizes how medication can substantially improve a child's life, and some parents pressure doctors to do something about their children's bad behavior and poor grades.

For his part, Adler, who is also director of the adult ADHD program at NYU Langone Medical Center, pointed out the importance of treating actual ADHD.

"The consequences, if ADHD is present, but untreated in young adults, are significant in that the risk for substance abuse, cigarette smoking, motor vehicle accidents, divorce or separation and under-performance on the job or in school are substantially elevated," Adler said.

Appropriate treatment "can include medication and psychosocial treatments, and should be established in careful cooperation of the patient, family and physician," he added. "Stimulant medications can be highly effective treatments with appropriate monitoring for improvement of symptoms of ADHD and for potential side effects."

More information

Learn more about ADHD from the U.S. National Institute of Mental Health.

- http://mobile.philly.com/health/?wss=/philly/health&id=200908211&viewAll=y#more

 

From the abstract:


"Medication status during follow-up, on versus off, did not predict symptom severity change from year 3 to year 6...ADHD in preschoolers is a relatively stable diagnosis over a 6-year period.The course is generally chronic, with high symptom severity and impairment, in very young children with moderate-to-severe ADHD, despite treatment with medication. Development of more effective ADHD intervention strategies is needed for this age group."

 

Recently, the American Academy of Pediatrics (AAP) revised its “Evidence-based Child and Adolescent Psycho-social Interventions” and elevated Brainwave Biofeedback to “Level 1 — Best Support” as an intervention for Attention & Hyperactivity Behaviors. 

"CNS Response's Psychiatric EEG Evaluation Registry, or PEER Online, is a cloud-based platform which allows physicians to exchange outcome data referenced to their patients' neurophysiology. 

Finding the right medication for an individual patient suffering from mental health issues is one of the biggest challenges facing medical professionals. Most mental health medications are currently prescribed through trial and error, a process that can be detrimental to patients and their families. Medications affect everyone differently, and with over 130 psychotropic medications to choose from, it is difficult for physicians to know which regimen is best. 

The PEER Online service will allow physicians to compare and learn which medication treatments have been effective, and which have not been effective for their peers treating patients with similar brain patterns. It builds on the company's original physician-developed database, Referenced-EEG® (rEEG®).

PEER Online is based on a transformative idea used to help treat pediatric cancer. In the 1970's, oncologists treating pediatric cancer developed a registry that helped them network and compare treatment regimens and patient outcomes, in order to advance knowledge of pediatric cancer. The system, which is still in place, enables physicians to learn what works and what does not for treating pediatric cancer, and has significantly improved children's cancer survival and recovery rates. 

As a cloud-based outcome registry, PEER Online will provide the same kind of vital exchange of information between medical professionals treating patients with mental health issues."

- http://www.cnsresponse.com/AboutPEEROnline.php

 

Recently the American Academy of Pediatrics placed Biofeedback as a Level 1 “Best Support” Intervention for ADHD (Attention and Hyperactivity Behaviors).  This affirms the success that we see in our clients with ADHD and is an important step forward in recognizing the powerful effects of Biofeedback in providing a non-invasive, non-drug treatment for a wide range of cognitive disorders. Here is what you need to know about this recent report:

What is the American Academy of Pediatrics?

The American Academy of Pediatrics is comprised of over 60,000 pediatricians.  Pediatricians refer to the AAP for its positions on pediatric care and pediatric practice guidelines.  When you see your pediatrician and ask your pediatrician questions, he or she is often informed by the policies, positions, and reports of the AAP.

What does “Best Support” mean?  How does the American Academy of Pediatrics make this determination?

Every six months the AAP updates their chart of “Evidence-Based Child and Adolescent Psychosocial Interventions.”  They evaluate the data and research that exist to determine what works and what doesn’t.  This information is passed on to pediatricians so that they can better serve their patients.  ”Best Support” indicates that the AAP has found that biofeedback is an effective treatment for ADHD and should be recommended as a primary option.  The chart may be viewed HERE.